Expertise in
1
conditions

Marc Kung

Fribourg, FR, CH 
Expertise in
1
conditions
Fribourg, FR, CH 

Overview

Marc Kung practices practicing medicine in Fribourg, Switzerland.

Mr. Kung is highly rated in 1 condition, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Glioblastoma, Astrocytoma, and Orchiectomy.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Fribourg, FR, Switzerland
Other Locations
Villars, JU 1752, Switzerland
Bern, BE, Switzerland
Kantonsspital Graubünden
Chur, GR, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Drug
Study Drug: ODM-201
Study Phase: Phase 2
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Other
Study Phase: Not Applicable
View 5 Less Clinical Trials

12 Total Publications

A retrospective cross-sectional survey of symptoms, comorbidities, return to work, and financial problems experienced by cancer survivors up to 10 years post-diagnosis.
A retrospective cross-sectional survey of symptoms, comorbidities, return to work, and financial problems experienced by cancer survivors up to 10 years post-diagnosis.
Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society
Published: May 20, 2026

Frequently Asked Questions about Marc Kung

Is Marc Kung a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Marc Kung is classified as an Advanced expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marc Kung participate in research or clinical trials?

Yes. Marc Kung has published 12 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Marc Kung's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kung's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile